Weight loss timeline projector

See how many weeks it'll take to reach your goal weight on tirzepatide, semaglutide, or retatrutide — based on published clinical-trial data.

Mounjaro / Zepbound · SURMOUNT-5 on-treatment estimand (72 weeks)

Enter your current and goal weight to see your timeline.

Educational projection only. Not a prescription, dosing recommendation, or weight-loss plan. Talk to a clinician about whether GLP-1 therapy is right for you.

How weight loss timelines actually work on GLP-1 medications

Weight loss with GLP-1 medications like semaglutide and tirzepatide usually happens gradually over several months, not days or weeks. Factors like starting weight, dosage increases, diet quality, activity level, sleep, and medication adherence can all affect how quickly results appear.

Many people experience the biggest changes after reaching maintenance doses of medications like Wegovy, Ozempic, Zepbound, or Mounjaro. Early progress may include water weight changes and appetite reduction, while longer-term results often depend on consistency and sustainable habits.

This weight loss timeline projector estimates potential progress over time based on your medication, dosage schedule, calorie intake, and weight loss goals.

Related GLP-1 weight loss guides

Weight loss plateaus are common during GLP-1 treatment, especially during dosage transitions or periods of inconsistent nutrition and sleep. Protein intake, hydration, resistance training, and medication timing can all influence long-term results.

Some people lose weight steadily throughout treatment, while others experience slower progress followed by larger changes after dose increases. Comparing progress week-to-week instead of day-to-day can provide a more realistic picture of long-term outcomes.

Want help optimizing nutrition during treatment? Use our GLP-1 meal planner to generate meal ideas that support appetite control, protein intake, and sustainable weight loss.

Questions about GLP-1 progress, plateaus, or weight loss expectations?

august is a private AI health companion that can help explain GLP-1 weight loss timelines, plateaus, side effects, dosage changes, appetite shifts, and long-term treatment expectations without a clinic visit or copay.

  • Private, no judgment
  • Available 24/7
  • Trained on health and wellbeing

Frequently Asked Questions

We apply published clinical-trial percent-change-from-baseline curves to your current weight and walk forward week by week until you hit your goal. Tirzepatide and semaglutide use the SURMOUNT-5 on-treatment estimand. Retatrutide 12 mg uses the published Phase 2 trial.

No. The curve reflects the average response in clinical trials — your actual loss can be faster, slower, or plateau differently. Variables like dose escalation, adherence, lifestyle, and individual physiology shift the curve. Treat this as a planning tool, not a promise.

It means your goal lies past the end of the published trial window. Beyond that point we extend the line at the slope of the trial's final weeks. It's our best read of the trend, but the published data doesn't cover it directly — confidence drops the further out you go.

Toggle "I'm already on this medication" and enter how many weeks you've been on it. We'll back-calculate your starting baseline from where you are on the curve and project forward from your current week.

We use Mifflin–St Jeor for basal metabolic rate, multiply by activity to get total daily energy expenditure, then apply a medication-class-specific deficit (about 25% for tirzepatide and retatrutide, 20% for semaglutide). Macros split 30% protein, 40% carbs, 30% fat — a high-protein default that supports lean mass during weight loss.

Tirzepatide and retatrutide tend to suppress appetite more strongly than semaglutide on a per-dose basis. The slightly larger deficit reflects the typical caloric reduction observed in their trials. The 1,200 kcal floor applies in either case.

The curves come from branded-drug trials. Compounded versions may produce different results — we don't ship a compounded-specific projection because there's no published RCT data to ground it. The branded curve is a reasonable starting estimate, with a wider error bar.

No. This is an educational projection tool, not a prescription, dosing recommendation, or weight-loss plan. Talk to a clinician about whether GLP-1 therapy is right for you and what realistic goals look like for your situation.

Your health journey starts with a single question

Download August today. No appointments. Just answers you can trust.

Download for iOSDownload for Android
Hand reaching for August Health app icon